logo
logo

Kedalion Therapeutics Secures Series B Funding And Announces Signing Of Option To Acquire Agreement

Nov 15, 2021•over 3 years ago

Round Type

series b

Menlo Park

Description

Kedalion Therapeutics is pleased to announce the completion of its Series B financing led by Novartis and involving a combination of new and existing investors. The Novartis investment includes an Exclusive Option to Acquire the company and its AcuStreamTM technology. This agreement follows a Feasibility Study agreement with the AcuStreamTM technology signed earlier this year. The subsequent feasibility study has been completed with successful results

Company Information

Company

Kedalion Therapeutics

Location

Menlo Park, California, United States

About

Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications. Kedalion’s proprietary AcuStream™ platform technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable effect with up to an 80% reduction in dose compared to standard eye drops. Kedalion is based in Menlo Park, CA. For more information, visit www.kedalionthera.com.